b.value AG

Our business is to turn scientists into entrepreneurs who can save lives and save the planet (we call this “human and planetary health”). Personal, 1 on 1, with IndieBio’s Team We are not an assembly line. You are not a widget. Every startup is unique and needs devoted attention. Most startup programs have a meeting with you once a week. We talk to you almost every day. We sit with you, desk to desk, as we work. These rapid touchpoints speed up your iteration cycles and are critical to your evolution into a successful startup. You get direct access to the team that helped build so many iconic companies over the years. Most accelerators are designed to spot the one company in 10 that might be big one day. At IndieBio, every startup matters. You are our first priority. Your success is our only business model. We only invest in companies that come through our accelerator. Our Alumni are Our Greatest Asset All new startups get the benefit of a trusted community with 199 alumni who are happy to share their wisdom. Going through IndieBio is an incredible bonding experience. We teach a philosophy and mindset that is uniquely ours. You’ll become emotionally and intellectually attached to your fellow batch mates. You’ll remember them the rest of your life. This deep connection informs the next years to come. IndieBio is our startups’ birthplace. Everyone visits home. Every generation of startups gets the benefit of alumni help, and then they repay the favor to the new batch. First, we can start funding you and working with you earlier, long before you’re ready to be in the intensive program. We’ve done this up to 9 months in advance. So even if you haven’t graduated yet, or haven’t yet gone full-time on the startup, we recommend you still apply. We Believe in Diversity 44% female. First, second, and third time founders. 36 nationalities. Post-docs and corporates. Ages 21 to 75. Diversity is a core thesis for IndieBio. We find talent that many others overlook. Some of the greatest companies of tomorrow are hiding in plain sight, today, right now. It’s just that nobody listens long and hard enough to recognize the brilliance and the potential. If other investors have told you that you’re “too early,” well, that’s our sweet spot. We’ve funded paper plans, where no science has been done yet–and created hugely successful companies that way. Perhaps the greatest endorsement is how many alumni have returned to IndieBio to create their second company. Choose SOSV as your Partner IndieBio’s parent is SOSV, which has $1 billion in assets under management, and is consistently a Top Quartile VC. SOSV runs programs around the world in robotics, biotech, mobile ecommerce, fintech, automated manufacturing, food, and cryptocurrencies. The firm was founded by Sean O’Sullivan, who had also been an entrepreneur and a humanitarian. In 2020, during the heat of the pandemic – when others were retreating – we were the most active investor in the US. We are now the 4th most active early stage investor in India. Our climate tech portfolio alone is worth over $6 billion. Partners for the Long-term The journey begins with $525,000 and our intense program. But we continue to invest meaningfully in every round. 80% of our capital is deployed post-accelerator. We recommend choosing your investors wisely. We offer the biggest checks in the accelerator industry, but that’s just the beginning. SOSV, our venture fund, is spread around the globe and manages $1.4 billion (as of September 16, 2022). We target a long-term ownership of around 10%, and we continue to invest at Seed through Series C. We are a long-term partner, not just a first-check accelerator. At IndieBio, we are in touch with thousands of investors, and we have co-invested with well over 400 firms. The SOSV network is even greater.

We help technical founders solve their hardest operational and commercialization challenges - all with an eye towards building durable, generational companies. We invest $500K-1M and frequently lead or co-lead. We invest from incorporation to seed stage, with more than 80% of our investments at pre-seed or earlier. Investing in two areas: biological platforms and applied robotics. Biological platforms encompass everything from material science to synthetic biology to AI for drug discovery. Applied robotics includes autonomy, chemical automation, swarm robotics systems, and biomanufacturing, among many others. Our North Star We believe there is a better way. Scientific and technological innovation drive our civilization forward, but the impact of these innovations is muted if they aren’t translated into real world projects. Too many times we’ve seen real scientific breakthroughs curtailed - or their impact delayed - not because of lack of rigor or founder ability, but because the infrastructure and tools don’t exist to commercialize these innovations in a repeatable manner. While scientific founders are sometimes able to raise early capital based on their technology or their backgrounds, the path between that initial funding and their first institutional round is maddeningly unclear and often treacherous. The entrepreneurs who do make it through that gauntlet often need to raise multiple rounds of dilutive capital to get there - stumbling in the dark until they understand what milestones they need to unlock that subsequent financing and build a successful business. Our North Star is helping entrepreneurs commercialize their breakthrough to build durable, impactful, and ultimately generational companies. Our team has founded, invested, and advised deep tech companies for over a decade. We’ve experienced the recessions, the hype cycles, the breakthroughs, and the breakouts. We’ve seen all of the many ways that deep tech companies can fail, but we’ve also seen founders beat the odds and build historic companies, legacies, and movements. It is our greatest privilege to partner with these entrepreneurs.

Unreasonable inventors are combining cutting edge scientific discoveries with the world's biggest challenges to build the next generation of global companies. These are the companies we create and invest in at Main Sequence. We have over $500m under management from lean-in LPs who help our portfolio to prosper. We are investing in the difficult to build companies others struggle to support. Our co-founder is Australia's $1.3b annual budget science agency - CSIRO We invest from seed to Series B, starting our journey as early as possible, driving advantage into our portfolio. Our Advantage Deep tech inventors need more. We have custom built Main Sequence to be ready to help you solve some of the world's greatest challenges with science. We are hands-on and have built a services offering to support founders alongside our capital. Our story Main Sequence was created by CSIRO to address the ‘valley of death’ between research and commercialisation. It solves the world’s greatest challenges by turning our scientific breakthroughs into the next century’s giants. Main Sequence’s origins within CSIRO reflect its commitment to amplifying connections between industry, research and infrastructure to accelerate deep technology development, and reinvesting economic returns from commercialisation back into science. CSIRO Innovation Funds 1 and 2 managed by Main Sequence, have invested in 39 companies since establishment in 2017. These companies have created over 1,200 jobs by working with partners in industry, CSIRO, and 22 Australian universities. The $240 million first CSIRO Innovation Fund , built on a cornerstone investment by government and CSIRO has completed its portfolio and invested in 27 companies since establishment in 2017. The second $300 million CSIRO Innovation Fund commenced investing mid-2021 and had already invested in 12 companies by the end of 2021. Following the Government’s announcement on 1 February 2022 of a reform agenda to accelerate commercialisation of research and collaboration with industry, including $150m support for CSIRO investment in future CSIRO Innovation Funds, Main Sequence welcomes the opportunity to continue to work closely with universities to commercialise Australian research and build Australian companies addressing global challenges. Each of our portfolio companies has some advantage delivered by either one of Australia's 43 universities or an industrial research organisation such as CSIRO. In some cases this exists before we invest, in others we facilitate it as part of the companies pathway to scale and impact.

We partner early with unstoppable entrepreneurs leveraging breakthrough science and technology to pursue progress at scale. Everything we do revolves around a single problem: What are the best ways to reconcile economic growth with human and planetary health? We invest in teams and solutions that address multi-decade problems that humanity has no choice but to solve. Our focusing questionsHow can we decouple improving living standards from resource depletion? How can we ensure food, energy and materials supply security when confronted by deglobalization, multipolarity and the distractions of the attention economy? How can we improve life on Earth and unlock future economic growth potential by leveraging next-generation computing and exploring outer space? How can the clean industrialization of biological processes reduce humanity’s impact on our planet? How we invest in unstoppable founders We look to problems and unmet needs first and then to which technologies and solutions have the potential to address those problems effectively. We don’t push any one type of technology or limit ourselves to one field. We look for founders and companies at the pre-seed and seed stages leveraging the three basic disciplines (physics, chemistry, biology) to engineer economically viable solutions. We look for teams that are uniquely suited to address the opportunity and its inherent challenges and for solutions that are radically better, technically viable, and defensible. Some of the areas we are keen to continue exploring include clean commodities, space technology, industrial decarbonization, electro- and green chemistry, next-generation computing, new materials & production methods. How we partner for the long-term Starlight is a Pre-Seed and Seed investor and ideally the first institutional check into your company. Having been in your shoes as founders and scientists ourselves, we will serve as an ally in the journey ahead. Here’s what you can expect from working with us: We will lead or co-lead your first institutional round. We reserve capital for follow-on investment in later rounds, and we have to ability to partner with our LPs to augment our participation in future opportunities. We will be personally invested in your success, as a large portion of our fund comes from our own team. We will put a particular focus on ensuring that your roadmap is focused on the key risks and milestones unique to addressing the most pressing problems. We will work with you to establish rock-solid governance and operational practices that hold up to the scrutiny of the world’s best institutional investors. We will help you line up and credibly engage the right future investors for your business and trajectory. Let’s partner and make change happen.

Oxygea is here to accelerate and invest in people and their business that will drive sustainable innovation and digital transformation. We value ecosystems and we cooperate with local and global networks to provide only the best to startups that will transform the future of the industry. Where do we invest? Circular Economy Technologies intended for reintegrating plastic waste to production chain Extend the useful lifecycle of plastic applications A reduction in the need for production, use, or disposal Carbon Neutrality Energy transition New materials from renewable sources Carbon market CO2 capture, storage and utilization for new chemicals Biotechnology/ Nanotechnology and New Materials New biological and biochemical routes to produce chemicals, plastics and materials Advanced Materials Digital technologies for accelerating R&D developments Plastic as sustainable solution Biopolymers Plastic applications with performance gain Additive manufacturing Smart Factory & Future Mobility Industry 4.0: Analytics, automation and advanced manufacturing technologies Logistics 4.0: Logistics efficiency and improved traceability

First dedicated fund investing in the Circular and Bio-Based Industries in Europe. As the first venture capital fund exclusively dedicated to the (circular-) bioeconomy, ECBF aims to catalyze the transition towards a sustainable future. Together with passionate and visionary entrepreneurs, we speed up the shift from a fossil-based to a circular bio-based economy and contribute to achieving the European Green Deal goals to make Europe climate neutral by 2050. For this purpose, we build pan-European market leaders by investing EUR 300m in growth-stage companies with high potential for innovation, favorable returns, and sustainable impact. In syndicates with private and public investors, we are offering flexible financing tools from equity to mezzanine. What is bioeconomy about? Bioeconomy is the transition from a fossil-based economy to a bio-based economy. This means that in the future we will have to rely on renewable biological resources to meet our needs for food, materials and energy. Therefore, it is our task to support innovative ideas that contribute to the creation of a sustainable future. An European Initiative The European Union (EU) intends to strengthen Europe's leading position in the circular bioeconomy. In 2017, the European Investment Bank (EIB) published a study stating that companies and projects in the European bioeconomy lack financing in the growth phase. This funding gap is affecting the transformation process in Europe from a linear to a sustainable circular economy. To address this gap, the EU has allocated EUR 100 million to establish a market-oriented European Growth Fund. At the end of 2018, the EIB launched a tender for the fund project. In a competitive process, the EIB selected the ECBF Management GmbH. ECBF's ESG guidelines, which guide the fund's investments, ensure that Europe's transformation to a more sustainable economy is supported.